Professor of Medicine
Department of Rheumatology
Leonard H. Calabrese, DO, has disclosed that he has received fees for non-CME/CE services from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, and UCB.
Baylor University Medical Center
Adjunct Professor of Medicine
University of Texas Southwestern Medical Center
Robert P. Perrillo, MD, FAASLD, has disclosed that he has received consulting fees from Dynavax.
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York
Andrew D. Zelenetz, MD, PhD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, and Roche, consulting fees from Adaptive Biotechnology, Amgen, Celgene, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, Janssen, Nanostring Tech, Novartis, Portola Pharmaceuticals, and Takeda, and holds membership with a data monitoring committee with Boehringer Ingelheim.
Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Editorial Director, Virology & Other Therapeutic Areas
Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for oncologists, rheumatologists, gastroenterologists, hepatologists, infectious disease physicians, and other healthcare professionals involved in the management of patients at risk for HBV reactivation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 18, 2016, through October 17, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
When and how to treat hepatitis B infection in women of childbearing age, in early pregnancy, and in late pregnancy.
Patients with hepatitis B may benefit from peginterferon if they need a limited duration of therapy, have genotype A HBV, or have hepatitis D coinfection.
Expert faculty members summarize key viral hepatitis studies from this important annual conference.
Following recent updates to the AASLD HBV guidelines, what criteria determine optimal therapy for immune-active CHB?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.